What development phase is Emepride in?

Emepride is FDA-approved (marketed).

What is the generic name of Emepride?

BROMOPRIDE is the generic (nonproprietary) name of Emepride.

Last reviewed 2026-04-20 · How we verify

Emepride (BROMOPRIDE)

FDA-approved active Small molecule Quality 19/100

Bromopride, marketed as Emepride, is a D(2) receptor antagonist used to reduce gastrointestinal motility, currently holding a position in the market with its key composition patent expiring in 2028. Its mechanism of action provides a distinct advantage over competitors by effectively managing gastrointestinal symptoms through selective dopamine receptor blockade. The primary risk to Bromopride's market position is the strong competition from metoclopramide, which has been FDA-approved since 1979 and will remain patent-protected until November 17, 2038.

At a glance

Generic name	BROMOPRIDE
Drug class	bromopride
Target	Acetylcholinesterase, D(2) dopamine receptor
Modality	Small molecule
Therapeutic area	Gastroenterology
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy of Bromopride and Simethicone Versus Bromopride in Functional Dyspepsia (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Emepride CI brief — competitive landscape report
Emepride updates RSS · CI watch RSS